Precigen, Inc. (NASDAQ:PGEN) Given Consensus Rating of “Moderate Buy” by Analysts

Precigen, Inc. (NASDAQ:PGEN) has earned an average rating of “Moderate Buy” from the five research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $10.00.

PGEN has been the topic of several research analyst reports. StockNews.com upgraded Precigen to a “sell” rating in a research report on Tuesday, May 21st. JMP Securities restated a “market outperform” rating and issued a $14.00 price objective on shares of Precigen in a research report on Tuesday, June 4th. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Precigen in a research report on Monday, June 3rd. Stifel Nicolaus boosted their price objective on Precigen from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, June 3rd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Precigen in a research report on Wednesday, May 15th.

Institutional Investors Weigh In On Precigen

A number of hedge funds have recently made changes to their positions in the company. Cetera Advisors LLC purchased a new stake in shares of Precigen in the first quarter worth about $367,000. EntryPoint Capital LLC bought a new stake in Precigen during the first quarter worth approximately $31,000. Vanguard Group Inc. increased its stake in Precigen by 0.3% during the first quarter. Vanguard Group Inc. now owns 6,768,234 shares of the biotechnology company’s stock worth $9,814,000 after acquiring an additional 19,875 shares during the last quarter. Iridian Asset Management LLC CT increased its stake in Precigen by 4.3% during the first quarter. Iridian Asset Management LLC CT now owns 2,091,274 shares of the biotechnology company’s stock worth $3,032,000 after acquiring an additional 86,340 shares during the last quarter. Finally, Fortis Group Advisors LLC bought a new stake in Precigen during the first quarter worth approximately $28,000. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Precigen Stock Performance

NASDAQ PGEN opened at $1.63 on Friday. The company has a market capitalization of $411.44 million, a PE ratio of -4.18 and a beta of 1.88. The business’s fifty day moving average is $1.43 and its 200 day moving average is $1.39. Precigen has a fifty-two week low of $0.84 and a fifty-two week high of $1.88.

Precigen (NASDAQ:PGEN) last released its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The company had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $1.54 million. Precigen had a negative net margin of 1,781.72% and a negative return on equity of 65.36%. During the same quarter last year, the firm posted ($0.10) earnings per share. On average, sell-side analysts forecast that Precigen will post -0.36 EPS for the current year.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.